Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage

The Journal of Urology
Qian ZhangJie Jin

Abstract

Identifying tumor suppressor genes silenced by promoter CpG methylation uncovers mechanisms of tumorigenesis and identifies new epigenetic biomarkers for early cancer detection. DLEC1 is located at 3p22.3, a critical tumor suppressor gene locus for renal cell carcinoma. We explored its epigenetic alteration in renal cell carcinoma and possible clinicopathological association. We examined DLEC1 expression and methylation by semiquantitative reverse transcriptase and methylation specific polymerase chain reaction in 9 renal cell carcinoma cell lines and 81 primary tumors. We also analyzed the relationship between DLEC1 methylation and clinicopathological features in patients with renal cell carcinoma. We assessed DLEC1 inhibition of renal cell carcinoma cell growth by colony formation assay. DLEC1 methylation and down-regulation were detected in all renal cell carcinoma cell lines. Treatment with 5-aza-2'-deoxycytidine (Sigma) and/or trichostatin A (Cayman Chemical, Ann Arbor, Michigan) reversed methylation and restored DLEC1 expression, indicating that methylation directly mediates its silencing. Aberrant methylation was further detected in 25 of 81 primary tumors (31%) but only 1 of 53 nonmalignant renal tissues (2%) showed met...Continue Reading

References

Jun 8, 2001·Proceedings of the National Academy of Sciences of the United States of America·K DreijerinkE R Zabarovsky
Mar 22, 2002·Nature Reviews. Cancer·A G Knudson
Jun 4, 2002·Nature Reviews. Genetics·Peter A Jones, Stephen B Baylin
Aug 10, 2002·Seminars in Oncology·John A Thompson
Aug 22, 2002·Human Molecular Genetics·Qian TaoKeith D Robertson
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Eva SingletaryFrederick L Greene
Jul 29, 2003·Urological Research·M T Sanz-CaslaL Resel
Oct 21, 2003·Genes, Chromosomes & Cancer·Stephan ImrehEugene R Zabarovsky
Jun 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Essel DulaimiPaul Cairns
Sep 10, 2005·International Journal of Cancer. Journal International Du Cancer·Daisuke YamadaYoshinori Murakami
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jianming YingQian Tao
Oct 19, 2006·Seminars in Oncology·Joseph K McLaughlinRobert E Tarone

❮ Previous
Next ❯

Citations

Jan 9, 2015·International Journal of Molecular Sciences·Ben XuJie Jin
Oct 9, 2012·European Urology·Kerstin JunkerEgbert Oosterwijk
Jul 4, 2012·Seminars in Cancer Biology·Eamonn R Maher
Feb 5, 2015·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Lian ZhangJie Jin
Mar 21, 2012·Epigenetics : Official Journal of the DNA Methylation Society·Christopher J RickettsEamonn R Maher
Jun 30, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Lu WangJianming Ying
Jan 6, 2019·Virchows Archiv : an International Journal of Pathology·Younghoon KimGyeong Hoon Kang
May 20, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Peng GeJian Lin
Jun 6, 2018·Nature Reviews. Urology·Sophie C JoostenManon van Engeland
Nov 5, 2020·Scientific Reports·Yu OkitsuKeiichiro Yogo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.